Serbia's Galenika to invest $40 million in new pharma facility in Russia

24 October 2018

Serbian drugmaker Galenika plans to build a new plant in Russia’s St Petersburg that will specialize on the production of its branded drugs, according to the company, reports The Pharma Letter’s local correspondent.

It is reported that implementation of the project will be part of Galenika’s current strategy of foreign expansion. The planned value of investments is estimated at $40 million.

Currently the company is conducting talks with the authorities of St Petersburg, regarding details of planned production, according to recent statements from the vice governor of St Petersburg, Igor Albin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK